The epidermal growth-factor-like domain A (EGF-A) of the low-density lipoprotein (LDL) receptor is a promising lead for therapeutic inhibition proprotein convertase subtilisin/kexin type 9 (PCSK9). However, clinical potential EGF-A limited by its suboptimal affinity PCSK9. Here, we use phage display to identify analogues with extended bioactive segments that have improved most potent analogue, ...